PDB4- COST-EFFECTIVENESS AND CARDIOVASCULAR RISK-AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Sep 1, 2001, 00:00
10.1046/j.1524-4733.2001.40202-121.x
https://www.valueinhealthjournal.com/article/S1098-3015(11)71278-5/fulltext
Title :
PDB4- COST-EFFECTIVENESS AND CARDIOVASCULAR RISK-AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71278-5&doi=10.1046/j.1524-4733.2001.40202-121.x
First page :
Section Title :
Open access? :
No
Section Order :
170